Beta Bionics, Inc. Common Stock (BBNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beta Bionics, Inc. Common Stock (BBNX) has a cash flow conversion efficiency ratio of -0.088x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.83 Million) by net assets ($271.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Beta Bionics, Inc. Common Stock balance sheet independence to measure how much of total assets are equity-financed.
Beta Bionics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Beta Bionics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore long-term investment intensity of Beta Bionics, Inc. Common Stock to see how much of total assets are deployed in long-term investments.
Beta Bionics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beta Bionics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Railway Harbin Group of Technology Corp. A
SHG:688459
|
N/A |
|
HelloFresh SE
XETRA:HFG
|
0.201x |
|
Yuanta Sec Kor
KO:003470
|
-0.033x |
|
Consensus Cloud Solutions Inc
NASDAQ:CCSI
|
1.226x |
|
Linewell Software Co Ltd
SHG:603636
|
0.034x |
|
London Stock Exchange Group PLC
LSE:LSEG
|
0.064x |
|
Perusahaan Perkebunan London Sumatra Indonesia Tbk PT
JK:LSIP
|
0.019x |
|
Raisecom Technology Co Ltd
SHG:603803
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Beta Bionics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Beta Bionics, Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Beta Bionics, Inc. Common Stock.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $287.61 Million | $-50.92 Million | -0.177x | +72.12% |
| 2024-12-31 | $76.01 Million | $-48.27 Million | -0.635x | -14.72% |
| 2023-12-31 | $58.61 Million | $-32.45 Million | -0.554x | +88.05% |
| 2022-12-31 | $13.00 Million | $-60.21 Million | -4.631x | -- |
About Beta Bionics, Inc. Common Stock
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Pa… Read more